Skip to content
Yale Cancer Center· @YaleCancer · X·· 2026-04-20Score60
Body · original

At #AACR26, Mengni He
@yalepathology
shares how spatial transcriptomics explains response vs resistance to sacituzumab govitecan for metastatic #breastcancer #MBC.
@YaleBreast

@AACR

@OncoAlert

@SmilowCancer

Heat 12 · 10 likes · 0 replies · 2 reposts

Conference abstracts
CT045matched by 药名 sacituzumab
Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer

Steven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays, Nathalie LeVasseur, Andreas Varkaris, William Randolph, Karunya Srinivasan, Shannon McCue, Zhenming Shun, Ke Liu, Zhen Su, Kevin Chin, Virginia Kaklamani, Kelly McCann, Erika Hamilton

Read the abstract →
CT275NCT07151586matched by 药名 sacituzumab
ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)

Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci

Read the abstract →

Source: Yale Cancer Center · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org